The utility of beta-blockers in the treatment of hypertension has created much speculation as to their efficacy in patients with comorbid conditions, and there are concerns regarding their adverse metabolic effects. It is important to note that these findings were observed with traditional beta-blockers, such as atenolol and metoprolol. The newer generation of beta-blockers, namely carvedilol and nebivolol, is changing the manner in which beta-blockers are viewed in hypertension management. Their ability to inhibit Al adrenoreceptors and influence nitric oxide leads to vasodilation, which traditional beta-blockers fail to do. These agents have been shown to have favorable metabolic effects while maintaining the beneficial cardiovascular effects of this drug class in post-myocardial infarction patients and the heart failure population.
